Biologische Behandlung als Therapieoption bei equinem Cushing-Syndrom

Tina Wassing

doi:10.1055/s-0033-1360206

Zeitschrift für Ganzheitliche Tiermedizin, Table of Contents

Zeitschrift für Ganzheitliche Tiermedizin 2014; 28(1): 19-29
DOI: 10.1055/s-0033-1360206

Ganzheitlicher Exkurs

Sonntag Verlag in MVS Medizinverlage Stuttgart GmbH & Co. KG Stuttgart · New York

Biologische Behandlung als Therapieoption bei equinem Cushing-Syndrom

Therapieansätze und Fallbeispiele aus der PraxisBiological treatment as therapy option for equine Cushingʼs syndrome: Therapy methods and case studies from veterinary practice

Tina Wassing

Abstract

All articles of this category

Zusammenfassung

Mit zunehmendem Alter erkranken Pferde häufig am equinen Cushing-Syndrom (ECS). Als Therapie werden konventionell in der Regel Pergolid-Präparate eingesetzt. Adjuvant oder als alleinige Therapie bietet sich eine biologische Behandlung an, die als Basistherapie Hypophysis suis-Injeel oder Glandula suprarenalis-Injeel je nach Ernährungszustand einsetzt, dazu als Katalysator-Präparat Coenzyme compositum bzw. Ubichinon compositum. Zusätzlich werden weitere 1–2 Präparate je nach vorherrschenden Symptomen des individuellen Falles angewandt, um die individuelle Symptomatik möglichst gut abzudecken. Anhand von 3 Fallbeispielen wird die Wirkung dieser biologischen Behandlung als alleinige oder adjuvante Therapie aufgezeigt.

Summary

With increasing age, horses often suffer from equine Cushingʼs syndrome. Conventionally, pergolide products are typically used as therapy. Biological treatment can be used as adjuvant or sole therapy by applying basic therapy of Hypophysis suis-Injeel or Glandula suprarenalis-Injeel, (depending on nutritional status) as well as the catalyst preparation Co-enzyme compositum or Ubiquinone compositum. In addition, 1–2 further preparations are applied depending on the predominant symptoms of the individual case by bearing in mind the individual symptoms as well. With the use of three case studies, the article discusses the effect of biological treatment either as sole or adjuvant therapy.

Key words

Cushingʼs disease - horse - biological treatment

Full Text

References

Literatur
1 Aleman M, Watson JL, Williams DC et al. Myopathy in horses with pituitary pars intermedia dysfunction (Cushingʼs disease). Neuromuscul Disord 2006; 16: 737-744
2 Beech J, Boston RC, McFarlane D et al. Evaluation of plasma ACTH, alpha-melanocyte-stimulating hormone, and insulin concentrations during various photoperiods in clinically normal horses and ponies and those with pituitary pars intermedia dysfunction. J Am Vet Med Assoc 2009; 235: 715-722
3 Bradaric Z. Untersuchung zum Equinen Cushing Syndrom und Prüfung der Wirksamkeit von Vitex agnus-castus (Mönchspfeffer) bei der Behandlung des Equinen Cushing Syndroms. [Diss. med. vet.]. Berlin: 2012
4 Brosnahan MM, Paradis MR. Assessment of clinical characteristics, management practices, and activities of geriatric horses. J Am Vet Med Assoc 2003; 223: 99-103
5 Carter RA, Geor RJ, Burton Staniar W et al. Apparent adiposity assessed by standardised scoring systems and morphometric measurements in horses and ponies. Vet J 2009; 179: 204-210
6 de Laat MA, Kyaw-Tanner MT, Sillence MN et al. Advanced glycation endproducts in horses with insulin-induced laminitis. Vet Immunol Immunopathol 2012; 145: 395-401
7 Donaldson MT, LaMonte BH, Morresey P et al. Treatment with pergolide or cyproheptadine of pituitary pars intermedia dysfunction (equine Cushingʼs disease). J Vet Intern Med 2002; 16: 742-746
8 Frank N, Andrews FM, Sommardahl CS et al. Evaluation of the combined dexamethasone suppression/thyrotropin-releasing hormone stimulation test for detection of pars intermedia pituitary adenomas in horses. J Vet Intern Med 2006; 20: 987-993
9 Frank N, Geor RJ, Bailey SR et al. Equine metabolic syndrome. J Vet Intern Med 2010; 24: 467-475
10 Froin HR. Das equine Cushing-Syndrom. Pathophysiologie und Diagnostik der hypophysären Dysfunktion der Pars intermedia. BPT-Kongress, 9.–12. 10. 1997, Münster. 1997.
11 Glover CM, Miller LM, Dybdal NO. Extrapituitary and pituitary pathological findings in horses with pituitary pars intermedia dysfunction: A retrospective study. J Equine Vet Sci 2009; 29: 146-153
12 Grenager N. How does Cushingʼs disease relate to laminitis? Advances in diagnosis and treatment. J Equine Vet Sci 2010; 30: 482-490
13 Iwen KA, Senyaman O, Schwartz A et al. Melanocortin crosstalk with adipose functions: ACTH directly induces insulin resistance, promotes a pro-inflammatory adipokine profile and stimulates UCP-1 in adipocytes. J Endocrinol 2008; 196: 465-472
14 Johnson PJ, Messer NT, Ganjam VK. Cushingʼs syndromes, insulin resistance and endocrinopathic laminitis. Equine Vet J 2004; 36: 194-198
15 Klammer S. Einfluss von POMC-Derivaten auf die Nebenniere. [Diss. med.]. Freiburg: 2007
16 Lee ZY, Zylstra R, Haritou SJ. The use of adrenocorticotrophic hormone as a potential biomarker of pituitary pars intermedia dysfunction in horses. Vet J 2010; 185: 58-61
17 McFarlane D. Advantages and limitations of the equine disease, pituitary pars intermedia dysfunction as a model of spontaneous dopaminergic neurodegenerative disease. Ageing Res Rev 2007; 6: 54-63
18 McFarlane D. Equine pituitary pars intermedia dysfunction. Vet Clin North Am Equine Pract 2011; 27: 93-113
19 McFarlane D, Dybdal N, Donaldson MT et al. Nitration and increased alpha-synuclein expression associated with dopaminergic neurodegeneration in equine pituitary pars intermedia dysfunction. J Neuroendocrinol 2005; a 17: 73-80
20 McFarlane D, Miller LM, Craig LE et al. Agreement in histologic assessments of the pituitary pars intermedia in aged horses. Am J Vet Res 2005; b 66: 2055-2059
21 McGowan CM. Endocrine disorders in the geriatric horse. Proc 48th BEVA, 9. – 12.9.2009, Birmingham/England. 2009.
22 McGowan CM, Frost R, Pfeiffer DU et al. Serum insulin concentrations in horses with equine Cushingʼs syndrome: response to a cortisol inhibitor and prognostic value. Equine Vet J 2004; 36: 295-298
23 McGowan TW, Hodgson DR, McGowan CM. The prevalence of equine Cushingʼs syndrome in aged horses. J Vet Intern Med 2007; 21: Abstract 113
24 Perkins GA, Lamb S, Erb HN, et al. Nydam DV Divers TJ. Plasma adrenocorticotropin (ACTH) concentrations and clinical response in horses treated for equine Cushingʼs disease with cyproheptadine or pergolide. Equine Vet J 2002; 34: 679-685
25 Potenza MA, Marasciulo FL, Chieppa DM et al. Insulin resistance in spontaneously hypertensive rats is associated with endothelial dysfunction characterized by imbalance between NO and ET-1 production. Am J Physiol Heart Circ Physiol 2005; 289: H813-822
26 Schott HC. Diagnosis and treatment of equine Cushingʼs disease. Proc 17th Congress IAEV, 4. – 6.2.2011, Montesilvano/Italien. 2011.
27 Schott HC. Pituitary pars intermedia dysfunction: equine Cushingʼs disease. Vet Clin North Am Equine Pract 2002; 18: 237-270
28 Sgorbini M, Panzani D, Maccheroni M et al. Equine cushing-like syndrome: diagnosis and therapy in two cases. Vet Res Commun 2004; 28 (Suppl. 01) 377-380
29 Treiber KH, Kronfeld DS, Geor RJ. Insulin resistance in equids: possible role in laminitis. J Nutr 2006; 136: 2094S-2098S
30 van der Kolk JH. Equine Cushingʼs disease. Equine Vet Education 1997; 9: 209-214
31 Walsh DM, McGowan CM, McGowan TW et al. Correlation of plasma insulin concentration with laminitis score in a field study of equine Cushingʼs disease and equine metabolic syndrome. J Equine Vet Sci 2009; 29: 87-94